Cargando…
Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design
Palivizumab for respiratory syncytial virus (RSV) immunoprophylaxis in premature infants poses a significant economic challenge. Although standard dosing of palivizumab results in unnecessary drug accumulation without additional clinical benefit, some clinicians have moved outside of evidence‐based...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363066/ https://www.ncbi.nlm.nih.gov/pubmed/30426719 http://dx.doi.org/10.1002/psp4.12364 |